Christian Brander obtained his PhD in Immunology from the University of Bern in 1994 for his studies on T-cell hypersensitivity to Penicillin and work on the mechanisms of exogenous antigen re-presentation on HLA class I. He completed his post-doctoral training at Harvard Medical School focusing on T cell immunity to HIV and studying the impact that host genetics have on these immune responses. He joined ICREA in 2008 with an appointment at the IrsiCaixa AIDS Research Institute. He has a special interest in the neurological consequences of HIV infection and the brain as a site of the viral reservoir. He works on the development of therapeutic HIV vaccine candidates and is a co-inventor of the HIV "HTI" immunogen, which is developed clinically by Aelix Therapeutics where he is a co-founder and CSO. He serves as the scientific director of the HIVACAT program, as a curator of the Los Alamos HIV Database and is an Associate Professor at the University of Vic.